These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 16262910)

  • 41. Pharmacovigilance program to monitor adverse reactions of recombinant streptokinase in acute myocardial infarction.
    Betancourt BY; Marrero-Miragaya MA; Jiménez-López G; Valenzuela-Silva C; García-Iglesias E; Hernández-Bernal F; Debesa-García F; González-López T; Alvarez-Falcón L; López-Saura PA;
    BMC Clin Pharmacol; 2005 Nov; 5():5. PubMed ID: 16262910
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early cardiac rupture following streptokinase in patients with acute myocardial infarction: retrospective cohort study.
    Polić S; Perković D; Stula I; Punda A; Lukin A; Rumboldt Z
    Croat Med J; 2000 Sep; 41(3):303-5. PubMed ID: 10962050
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypotension in acute myocardial infarction patients given streptokinase.
    Lateef F; Anantharaman V
    Singapore Med J; 2000 Apr; 41(4):172-6. PubMed ID: 11063182
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adverse drug reaction monitoring in a secondary care hospital in South India.
    Arulmani R; Rajendran SD; Suresh B
    Br J Clin Pharmacol; 2008 Feb; 65(2):210-6. PubMed ID: 17662089
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Heberkinasa: recombinant streptokinase.
    Hernández L; Martinez Y; Quintana M; Besada V; Martinez E
    Eur Heart J; 2005 Aug; 26(16):1691. PubMed ID: 15946953
    [No Abstract]   [Full Text] [Related]  

  • 46. Recombinant streptokinase: evidences from clinical use.
    Llerena LD; Cáceres-Lóriga FM; Betancourt BY
    Eur Heart J; 2005 Jul; 26(14):1448-9; author reply 1449-50. PubMed ID: 15905301
    [No Abstract]   [Full Text] [Related]  

  • 47. The poor quality of streptokinase products in use in developing countries.
    Longstaff C; Thelwell C; Whitton C
    J Thromb Haemost; 2005 May; 3(5):1092-3. PubMed ID: 15869616
    [No Abstract]   [Full Text] [Related]  

  • 48. Comparative analysis of the activity and content of different streptokinase preparations.
    Hermentin P; Cuesta-Linker T; Weisse J; Schmidt KH; Knorst M; Scheld M; Thimme M
    Eur Heart J; 2005 May; 26(9):933-40. PubMed ID: 15637085
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Angiographic patency study of an albumin-free recombinant streptokinase formulation in acute myocardial infarction.
    Llerena LD; Quirós JJ; Sainz B; Valdés JA; Zorio B; Villanueva LH; Filgueiras CE; Cabrera F; Echarte JC; Pérez del Todo JM; Guerrero I; López L; García EJ; Nadal B; Betancourt BY; Díaz-Rojo G; García AI; López-Saura P
    J Pharm Pharm Sci; 2004 Nov; 7(3):372-7. PubMed ID: 15576019
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction).
    Antman EM; Anbe DT; Armstrong PW; Bates ER; Green LA; Hand M; Hochman JS; Krumholz HM; Kushner FG; Lamas GA; Mullany CJ; Ornato JP; Pearle DL; Sloan MA; Smith SC; ; ;
    J Am Coll Cardiol; 2004 Aug; 44(3):671-719. PubMed ID: 15358045
    [No Abstract]   [Full Text] [Related]  

  • 51. Stabilization of a freeze-dried recombinant streptokinase formulation without serum albumin.
    López M; González LR; Reyes N; Sotolongo J; Pujol V
    J Clin Pharm Ther; 2004 Aug; 29(4):367-73. PubMed ID: 15271104
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial.
    Al-Khatib SM; Stebbins AL; Califf RM; Lee KL; Granger CB; White HD; Armstrong PW; Topol EJ; Ohman EM;
    Am Heart J; 2003 Mar; 145(3):515-21. PubMed ID: 12660676
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interaction between arrival time and thrombolytic treatment in determining early outcome of acute myocardial infarction.
    Wilkinson J; Foo K; Sekhri N; Cooper J; Suliman A; Ranjadayalan K; Timmis AD
    Heart; 2002 Dec; 88(6):583-6. PubMed ID: 12433884
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Spontaneous reporting of adverse drug reactions in Cuba: integrating continuous education, training and research in a network approach.
    Debesa F; Jiménez G; Figueras A; Diogène E; Pérez Peña J; Avila J; Laporte JR
    Br J Clin Pharmacol; 2002 Sep; 54(3):335-6. PubMed ID: 12236857
    [No Abstract]   [Full Text] [Related]  

  • 55. TERIMA-2: national extension of thrombolytic treatment with recombinant streptokinase in acute myocardial infarct in Cuba.
    TERIMA Group of Investigators
    Thromb Haemost; 2000 Dec; 84(6):949-54. PubMed ID: 11330244
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.